218 IMPACT-DCM: A Randomized, Controlled, Multi-Center Phase II Trial Utilizing Expanded Autologous Bone Marrow as Sole Therapy for Dilated Cardiomyopathy Study Update

B.A Bruckner,N.G Smedira,O.M Lattouf,B.L Hamman,A Ghodsizad,D.A Bull,A.N Patel,E Burchardt

doi:10.1016/j.healun.2011.01.225

218 IMPACT-DCM: A Randomized, Controlled, Multi-Center Phase II Trial Utilizing Expanded Autologous Bone Marrow as Sole Therapy for Dilated Cardiomyopathy Study Update

B.A Bruckner, N.G Smedira + Show 6 more

https://doi.org/10.1016/j.healun.2011.01.225

Copy DOI

Journal: The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation	Publication Date: Apr 1, 2011
Citations: 1

Affiliation: Methodist Hospital, Aastrom Biosciences (United States)

#Sole Therapy #Severe Heart Failure + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

Autologous expanded bone marrow is used as sole therapy to treat no-option patients suffering from dilated cardiomyopathy (DCM) associated with severe heart failure in a multi-center phase II study (IMPACT-DCM, Sponsored by Aastrom Biosciences, Inc).

Full Text